Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...
Month: April 2024
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the...
Synopsys Accelerates Next-Level Chip Innovation on TSMC Advanced Processes
Collaboration on AI-Driven Design Flows for Optimization and Productivity, Advancements in Photonic IC Integration, Plus Broad IP Development on TSMC...
Sleep Number Announces First Quarter 2024 Results
Net sales of $470 million; adjusted EBITDA of $37 million slightly ahead of expectations Reduced operating expenses by $24 million...
SEI Reports First-Quarter 2024 Financial Results
OAKS, Pa., April 24, 2024 /PRNewswire/ -- SEI Investments Company (NASDAQ:SEIC) today announced financial results for the first-quarter 2024. Diluted earnings...
Sabra Health Care REIT, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call
Contacts Investor & Media Inquiries: 1-888-393-8248 or investorinquiries@sabrahealth.com Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Pixelworks to Announce First Quarter 2024 Financial Results on May 14
PORTLAND, Ore., April 24, 2024 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative video and display processing...
Personalis to Announce First Quarter 2024 Financial Results
Contacts Investors: Caroline Corner investors@personalis.com 415-202-5678 Media: pr@personalis.com Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced...
Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today...
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Contacts Investor Contacts: Pulse Biosciences Kevin Danahy, President and CEO 510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip Taylor 415.937.5406 philip@gilmartinir.com...
Dave & Buster’s Appoints New Chief Financial Officer
DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), ("Dave & Buster's" or "the Company"),...
Pega Delivers Outstanding Cash Flow and Margin Expansion in Q1 2024
Cash flow from operations and free cash flow both reach $180 million Annual contract value (ACV) grows 9% year over...
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...
NVE Schedules Conference Call on Fourth-Quarter and Fiscal Year Results
EDEN PRAIRIE, Minn., April 24, 2024 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced that it plans to release its...
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company...
Meta Reports First Quarter 2024 Results
MENLO PARK, Calif., April 24, 2024 /PRNewswire/ -- Meta Platforms, Inc. (Nasdaq: META) today reported financial results for the quarter...
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing...
Leafly to Announce First Quarter 2024 Financial Results on May 9, 2024
Contacts Investors ir@leafly.com Media pr@leafly.com Leafly Holdings, Inc. (“Leafly” or “the Company”) (NASDAQ: LFLY), a leading online cannabis discovery marketplace...
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated...
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass., April 24,...
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the...
Inter Parfums, Inc. Reports Record 2024 First Quarter Net Sales
Reaffirms 2024 Sales Guidance Contacts Inter Parfums, Inc. Michel Atwood Chief Financial Officer (212) 983-2640 www.interparfumsinc.com or The Equity Group...
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology...
InnovAge Launches PACE Center in Los Angeles, Helping Seniors Live Independently with High-Quality Care
LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), the healthcare industry leader in providing...
The Honest Company to Report First Quarter Financial Results on May 8, 2024
LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a personal care company dedicated to creating...
HMN Financial, Inc. Announces Dividend
ROCHESTER, Minn., April 24, 2024 (GLOBE NEWSWIRE) -- HMN Financial, Inc. (HMN or the Company) (Nasdaq:HMNF) today announced that its...
Katahdin Bankshares Corp. Reports First Quarter 2024 Results
HOULTON, Maine, April 24, 2024 /PRNewswire/ -- Katahdin Bankshares Corp. (OTCQX: KTHN), the parent company of Katahdin Trust Company, a full-service...
Heritage Global to Announce First Quarter 2024 Results and Host Webcast on Thursday, May 9, 2024
Contacts Investor Relations: John Nesbett/Jennifer Belodeau IMS Investor Relations 203/972.9200 InvestorRelations@hginc.com Heritage Global Inc. (NASDAQ: HGBL) (“Heritage Global,” “HG” or...
Great Lakes Announces New $150,000,000 Second-Lien Financing Agreement
HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD),...
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher diseasePoster presentation to highlight Freeline’s GBA1 Parkinson’s...
Finward Bancorp Announces Earnings for the Quarter Ended March 31, 2024
MUNSTER, Ind., April 24, 2024 (GLOBE NEWSWIRE) -- Finward Bancorp (Nasdaq: FNWD) (the “Bancorp”), the holding company for Peoples Bank...
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose...
Cytokinetics to Announce First Quarter Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled...
Cadence and TSMC Collaborate on Wide-Ranging Innovations to Transform System and Semiconductor Design
Highlights: Cadence’s best-in-class Integrity 3D-IC platform supercharged with new features Revolutionary AI-driven digital and custom/analog full flows and optimized for...
National Capital Bancorp, Inc. Reports First Quarter Earnings
Contacts Randal J. Rabe, EVP, Chief Financial Officer Phone: 202-546-8000 Email: rrabe@nationalcapitalbank.bank National Capital Bancorp, Inc. (the “Company”) (OTC Pink:...
Kimball Electronics, Inc. Announces Date For Reporting Third Quarter Fiscal Year 2024 Financial Results
Contacts Andrew D. Regrut Vice President, Investor Relations 812.827.4151 Investor.Relations@kimballelectronics.com Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will...
Smith-Midland Announces Receipt of Nasdaq Letter
MIDLAND, VA / ACCESSWIRE / April 24, 2024 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary...